Mission Therapeutics Ltd has appointed Michael Koslowski as chief medical officer to help the company advance its portfolio of experimental oncology drugs. Dr Koslowski was previously head of clinical services and early development at Glenmark Pharmaceuticals where he led that company’s first oncology development programme. Prior to this, he was global head of translational medicine experts at Boehringer Ingelheim GmbH.
Dr Koslowski has also been an associate professor of molecular medicine at the University of Mainz in Germany.
Mission Therapeutics announced the appointment on 1 September 2015.
Copyright 2013 Evernow Publishing Ltd